Area of Research
Murray Krahn’s research evaluates the effectiveness, cost-effectiveness and feasibility of integrating new drugs, technologies and services into the health care system, with a primary interest in prostate cancer and viral hepatitis.
Krahn holds a Tier 1 Canada Research Chair in Health Technology Assessment and is director of THETA (Toronto Health Economics and Technology Assessment Collaborative), a multidisciplinary research collaboration that aims to provide evidence-informed advice to health technology policymakers.
New drugs and technologies are continuously being developed, but not all of them are integrated into the health care system. A new drug or technology may demonstrate excellent benefits during testing, but it may not be appropriate for real clinical applications because it is too expensive, induces harmful side effects, has a high failure rate or is impractical for clinical use. For policymakers to decide whether a drug or technology should be implemented, they must weigh the demonstrated benefits against the costs.
Krahn’s team uses tools such as economic modelling, randomized trials and large administrative datasets to evaluate whether specific drugs and technologies should be implemented in the health care system. His team also uses qualitative methods to study the perspectives of the stakeholders that use or administer these products and identify ways of optimizing their use so that they can be implemented successfully.
Impact To Date
Krahn’s work has been important in evaluating the feasibility of many drugs, technologies and services for the treatment or screening of hepatitis C, heart failure, prostate cancer and other conditions. His work has influenced health policy decisions and changes from the institutional to national level.